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Using fluorescence *in situ*hybridization (FISH), we previously showed that the *LRIG1*gene had an increased copy number in 11 of 28 (39%) breast cancer tumours \[[@B1]\]. The *LRIG1*gene (leucine-rich repeats and immunoglobulin-like domains 1) at chromosome 3p14 is a proposed tumour suppressor gene that negatively regulates various receptor tyrosine kinases, including the breast cancer proto-oncogene product ERBB2 \[[@B2],[@B3]\].

Recently, however, Miller and colleagues \[[@B4]\] showed that 10 of 13 (76%) ERBB2^+^tumours had decreased LRIG1 protein levels compared to normal breast tissue. As their data showed down-regulation at the protein level whereas our data showed an increased copy number at the genomic level, we analysed 45 additional breast tumours by FISH as previously described \[[@B1]\]. Thus, out of 73 tumours analysed to date, 25 (34%) did indeed have increased *LRIG1*copy number. To further analyse the relationship between *LRIG1*and *ERBB2*at the genomic level, we evaluated the *ERBB2*gene copy numbers in 18 tumours with increased *LRIG1*copy number using FISH analysis according to standard procedures. Interestingly, 16 (89%) out of the 18 tumours displayed increased copy number of *ERBB2*(Figure [1](#F1){ref-type="fig"}). This suggests that the majority of breast cancer tumours with increased copy number of *ERBB2*simultaneously had increased *LRIG1*copy number (our data) and decreased LRIG1 protein levels \[[@B4]\].

![**Increased copy number of *LRIG1*and *ERBB2*in human breast cancer in the same patient**. Interphase nuclei from a breast cancer tumour were analysed by FISH. **(a)**A specific *LRIG1*probe (red) showed increased *LRIG1*copy number (five copies) whereas a specific centromere probe (CEP3) (green) showed normal chromosome 3 copy number (two copies). **(b)**A specific *ERBB2*probe (red) showed amplification of the *ERBB2*gene whereas a specific centromere probe (CEP17; green) showed three copies of chromosomes 17.](bcr2248-1){#F1}

We draw the following major conclusions from these results. First, as previously shown, a significant proportion of breast tumours have an increased *LRIG1*gene dosage. Second, there is a correlation between increased gene copy numbers of *ERBB2*and *LRIG1*. Third, based on the Miller protein data, most of the tumours with increased *LRIG1*gene dosage express reduced levels of the LRIG1 protein. This indicates a negative selection against LRIG1 protein expression, supporting the notion that *LRIG1*is a tumour suppressor in breast cancer. Although the mechanism behind the down-regulation of LRIG1 protein in breast cancer is not known, it has been reported that increased gene copy numbers in some cases are associated with decreased mRNA expression \[[@B5]\]. In any case, the high frequency (34%) of tumours with increased *LRIG1*gene copy number implies a positive selection for tumour cells with this genomic alteration. It remains, however, to be elucidated whether the molecular driver behind the selective advantage associated with this alteration is LRIG1 down-regulation *per se*. Other possibilities include activation of nearby proto-oncogenes or the generation of novel oncogenic fusion genes.

In summary, the co-incidental increase in copy number of *ERBB2*and *LRIG1*in breast cancer is a novel finding, pointing at a functional co-operation between these genetic events, where the biological and clinical importance need to be clarified further.
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